Background illustration for clinical trials search

Triple Negative Breast Cancer Clinical Trials

Browse 163 triple negative breast cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

Neoadjuvant INBRX-106 in Combination With Pembrolizumab for Stage II/III TNBC Patients

for
Triple Negative Breast Cancer
Location: Portland OR, Los Angeles CA
Sponsor: Providence Health & Services

Sex: All

Age: 18+

Code: NCT06353997

Phase2, Recruiting

Alpelisib/iNOS Inhibitor/Nab-paclitaxel in Patients With HER2 Negative Metaplastic Breast Cancer (MpBC)

for
HER2-negative Breast Cancer, Metastatic Breast Cancer,
Location: Bethesda MD, Houston TX
Sponsor: The Methodist Hospital Research Institute

Sex: All

Age: 18+

Code: NCT05660083

Phase2, Recruiting

Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC

for
Breast Cancer, Triple Negative Breast Cancer, PD-L1 Negative
Location: Brewer ME, South Weymouth MA, Boston MA, Foxborough MA,
Sponsor: Dana-Farber Cancer Institute

Sex: All

Age: 18+

Code: NCT04468061

Phase2, Recruiting

This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors

for
Non Small Cell Lung Cancer,
Location: Boston MA, Austin, TX 78758 TX, San Antonio TX
Sponsor: Zumutor Biologics Inc.

Sex: All

Age: 18+

Code: NCT06451497

Phase1, Recruiting

Study of AVZO-021 in Patients With Advanced Solid Tumors

for
Advanced Solid Tumor, HR+/HER2- Breast Cancer,
Location: Mineola NY, New York NY, Sarasota FL, Portland OR,
Sponsor: Avenzo Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05867251

Phase1, Phase2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)

for
Triple Negative Breast Cancer
Location: Scarborough ME, South Weymouth MA, Boston MA,
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT05633654

Phase3, Recruiting

Breast Cancer PSMA PET

for
Triple Negative Breast Cancer
Location: Iowa City IA
Sponsor: Ahmad Shariftabrizi

Sex: Female

Age: 18 - 70+

Code: NCT06586047

Early_phase1, Recruiting

Open-label, Single Center, Single-arm, Phase 2 Study of Neoadjuvant Pembrolizumab in Combination With Carboplatin and Paclitaxel in Patients With Stage 1 cT1b-T1cN0M0 Triple Negative Breast Cancer

for
Stage 1 cT1b-T1cN0M0, Triple Negative Breast Cancer
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT06318897

Phase2, Recruiting

A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer

for
Breast Cancer, Metastatic Triple-Negative Breast Cancer
Location: Commack NY, Uniondale NY, Harrison NY, New York NY,
Sponsor: Memorial Sloan Kettering Cancer Center

Sex: All

Age: 18+

Code: NCT05570253

Phase2, Recruiting

Sacituzumab Govitecan In TNBC

for
Invasive Breast Cancer, Triple Negative Breast Cancer,
Location: Danvers MA, Boston MA, Newton MA
Sponsor: Massachusetts General Hospital

Sex: All

Age: 18+

Code: NCT04230109

Phase2, Recruiting

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

for
Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary,
Location: Providence RI, New Haven CT, New York NY, Baltimore MD,
Sponsor: Volastra Therapeutics, Inc.

Sex: All

Age: 18+

Code: NCT05902988

Phase1, Phase2, Recruiting

CtDNA Based MRD Testing for NAC Monitoring in TNBC

for
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
Location: Stony Brook NY, York PA, Washington DC DC,
Sponsor: Personalis Inc.

Sex: Female

Age: 18+

Code: NCT06230185

Recruiting

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)

for
Advanced Solid Tumor, Advanced Malignant Neoplasm,
Location: Boston MA, New Haven CT, New York NY, Philadelphia PA,
Sponsor: PMV Pharmaceuticals, Inc

Sex: All

Age: 12+

Code: NCT04585750

Phase1, Phase2, Recruiting

Correlation of Clinical Response to Pathologic Response in Patients With Early Breast Cancer

for
Breast Cancer, Breast Neoplasm, Breast Cancer Female,
Location: Houston TX
Sponsor: Baylor Breast Care Center

Sex: All

Age: 18+

Code: NCT05020860

Phase2, Recruiting

A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer

for
Triple Negative Breast Cancer
Location: Norfolk VA, Atlanta GA, Nashville TN, Germantown TN,
Sponsor: Gilead Sciences

Sex: All

Age: 18+

Code: NCT06926920

Phase1, Phase2, Recruiting

NearWave Optical Molecular Monitoring

for
Breast Cancer, HER2-positive Breast Cancer,
Location: Indianapolis IN
Sponsor: Indiana University

Sex: Female

Age: 18+

Code: NCT06744465

Recruiting

Neratinib in Combination With Ruxolitinib in Patients With mTNBC

for
Metastatic Triple-Negative Breast Carcinoma, Breast Cancer
Location: Dallas TX
Sponsor: Baylor Research Institute

Sex: Female

Age: 18+

Code: NCT06008275

Early_phase1, Recruiting

Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform

for
Early Stage Triple-Negative Breast Carcinoma,
Location: Jacksonville FL, Rochester MN, Phoenix AZ
Sponsor: Mayo Clinic

Sex: All

Age: 18+

Code: NCT06349642

Recruiting

Testing the Combination of the Anticancer Drugs ZEN003694 and Binimetinib in Patients With Advanced/Metastatic or Unresectable Solid Tumors With RAS Alterations and Triple Negative Breast Cancer

for
Advanced Malignant Solid Neoplasm,
Location: Houston TX
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT05111561

Phase1, Recruiting

A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)

for
Breast Neoplasms, Triple Negative Breast Neoplasms,
Location: St. John's, Westbrook ME, Boston MA, Quebec, Sherbrooke,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT06966700

Phase3, Recruiting